Urinary Bladder Neoplasms Clinical Trial
Official title:
A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Verified date | November 2022 |
Source | Janssen Research & Development, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
Status | Completed |
Enrollment | 35 |
Est. completion date | September 15, 2022 |
Est. primary completion date | December 23, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histological proof of non-metastatic muscle-invasive urothelial cell carcinoma of the bladder - Participant must have been as fully resected as possible per the physician's judgment - Participants must be deemed unfit for RC due to comorbid conditions with a risk of mortality - Participants must refuse or be deemed ineligible for cisplatin-based chemotherapy - Participant must refuse or not be eligible for radiotherapy Exclusion Criteria: - Other active malignancies - Presence of any bladder or urethral anatomic feature that in the opinion of the Investigator may prevent the safe placement, indwelling use, or removal of TAR-200 - Pyeloureteral tube externalized to the skin (ureteral stent or unilateral nephrostomy tube is allowed) - Evidence of bladder perforation during diagnostic cystoscopy - Concurrent clinically significant infections as determined by the treating Investigator |
Country | Name | City | State |
---|---|---|---|
Spain | Fundacion Puigvert | Barcelona | |
Spain | Hosp. Univ. 12 de Octubre | Madrid | |
Spain | Inst. Valenciano de Oncologia | Valencia | |
United States | North Austin Urology | Austin | Texas |
United States | North Georgia Urology Center | Dalton | Georgia |
United States | Chesapeake Urology Research Associates | Hanover | Maryland |
United States | Urology Associates, PC | Nashville | Tennessee |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Mayo Clinic Arizona | Phoenix | Arizona |
United States | University of Rochester | Rochester | New York |
United States | Michigan Institute of Urology | Troy | Michigan |
United States | Urology of Virginia, PLCC | Virginia Beach | Virginia |
Lead Sponsor | Collaborator |
---|---|
Janssen Research & Development, LLC |
United States, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | An Adverse Event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. | Up to Day 84 | |
Secondary | Percentage of Participants with Clinical Complete Response (cCR) | Percentage of Participants with Clinical Complete Response (cCR) will be reported as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated). | Up to Day 360 | |
Secondary | Percentage of Participants with Clinical Partial Response (cPR) | Percentage of participants with clinical partial response (cPR) will be reported as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated). | Up to Day 360 | |
Secondary | Percentage of Participants with Stable Disease (SD) | Percentage of participants with stable disease (SD) will be reported as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated). | Up to Day 360 | |
Secondary | Percentage of Participants with Disease Progression | Percentage of participants with disease progression as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated) | Up to Day 360 | |
Secondary | Symptom Control | Symptom Control is defined as changes in bladder-related symptoms per the protocol-specified bladder symptom (Urinary frequency, Nocturia, Hematuria and Dysuria/pain) and toxicity grading system (Grade 0-3). | Up to Day 360 | |
Secondary | Time to Intervention for Symptom Control | Time to intervention for symptom control, defined as the time from the date of the first TAR-200 insertion to the date of intervention for symptom palliation. | Up to Day 360 | |
Secondary | Time to Progression | Time to progression, defined as the time from the date of the first TAR-200 insertion to the date of first occurrence of progression. | Up to Day 360 | |
Secondary | Percentage of Participants Undergoing Post-treatment Interventions by 3, 6, 9, and 12 Months | Percentage of participants undergoing post-treatment interventions for the management of local symptoms by 3, 6, 9, and 12 months. | Up to 3, 6, 9, and 12 Months | |
Secondary | Percentage of Participants Surviving at 12, 24, and 36 Months | Percentage of participants surviving at 12, 24, and 36 months compared to all participants. | At 12, 24, and 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02612194 -
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02805608 -
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02534623 -
Postoperative Quality of Recovery After Transurethral Resection of the Bladder
|
N/A | |
Recruiting |
NCT02228473 -
Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
|
N/A | |
Completed |
NCT02778243 -
Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level
|
N/A | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Terminated |
NCT02560038 -
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02252445 -
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
|
N/A | |
Not yet recruiting |
NCT02760953 -
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
|
N/A | |
Terminated |
NCT04430036 -
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT06289283 -
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
|
||
Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03661320 -
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
|
Phase 3 | |
Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT01479348 -
Imaging Study for FdCyd and THU Cancer Treatment
|
Early Phase 1 | |
Recruiting |
NCT05742867 -
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
|
||
Recruiting |
NCT03973671 -
Prospective Sample Collection for Cancer of Bladder
|